Pertuzumab

A new treatment combining trastuzumab deruxtecan (T-DXd) with pertuzumab reduced the risk of disease progression or death by 44% compared to standard care in HER2-positive metastatic breast cancer patients.

• Researchers from RWJBarnabas Health and Rutgers Cancer Institute will showcase 45 innovative cancer studies at the 2025 ASCO Annual Meeting, highlighting advances across multiple tumor types and treatment approaches. • A notable multisite randomized trial demonstrated that problem-solving skills training significantly improved depression, anxiety, and quality of life in young adults newly diagnosed with cancer compared to standard care. • New research revealed that patients living in both food and clinical trial deserts had 27% lower likelihood of breast cancer trial enrollment, highlighting how geographic and socioeconomic barriers impact cancer care access.

ENHERTU combined with pertuzumab demonstrated superior progression-free survival compared to standard taxane, trastuzumab and pertuzumab therapy as first-line treatment for HER2 positive metastatic breast cancer in the DESTINY-Breast09 phase 3 trial.

AstraZeneca will present over 80 abstracts at ASCO 2025, including two plenary presentations featuring camizestrant for HR-positive breast cancer and IMFINZI for early gastric cancer, marking their seventh consecutive year with plenary data.

• China's National Medical Products Administration (NMPA) has approved Remegen's antibody-drug conjugate disitamab vedotin (RC-48) for patients with HER2-positive advanced breast cancer with liver metastasis. • The approval marks a significant advancement in targeted therapy options for Chinese patients with advanced breast cancer, particularly addressing the challenging subset with liver metastases. • Disitamab vedotin joins the growing field of antibody-drug conjugates targeting HER2, offering a new treatment approach in a market where targeted therapies for metastatic breast cancer remain an area of high unmet need.